Vasopressor Use in Surgical Patients: Choosing the Right Agent

• Mean Arterial Pressure (MAP): Common target ≥65 mmHg (adjusted for chronic hypertension or organ perfusion concerns).
• Goal: Restore perfusion, prevent organ dysfunction, avoid excessive vasoconstriction.

• Hypovolemic Shock
• • Cause: Bleeding, fluid loss (trauma, surgical blood loss).
  • First-line: Fluids and blood products; vasopressors only if persistent hypotension after resuscitation.
• Distributive Shock (e.g., Septic, Anaphylactic)
• • Cause: Inflammatory vasodilation.
  • Requires vasopressors early, in addition to fluids.
• Cardiogenic Shock
• • Cause: Myocardial infarction, cardiac surgery complications.
  • Requires agents with inotropy and afterload management.

• Mechanism: Strong α1 (vasoconstriction), mild β1 (inotropy).
• Use: First-line in distributive/septic shock in surgical patients.
• Why: Restores vascular tone with limited tachycardia.

• Mechanism: Pure α1 agonist.
• Use: Good for intraoperative hypotension due to anesthesia-induced vasodilation.
• Caution: May reduce cardiac output in hypovolemic or poor LV function patients.

• Mechanism: Potent α and β effects.
• Use: Anaphylaxis, refractory shock, cardiac arrest.
• Why: Adds inotropy/chronotropy; risks arrhythmias and lactate rise.

• Mechanism: V1 receptor agonist → vasoconstriction independent of catecholamines.
• Use: Adjunct in septic/distributive shock; helpful in acidosis or catecholamine resistance.
• In OR: Useful when norepinephrine alone inadequate.

• Low doses: Dopaminergic renal vasodilation (not clinically useful).
• Moderate doses: β1 effects (inotropy).
• High doses: α1 vasoconstriction.
• Limitations: Increased risk of arrhythmias; largely replaced by norepinephrine/epinephrine.

MAP (mean arterial pressure) is a really important piece when you’re thinking about shock!

Let’s anchor this:

• In critical care, we usually target MAP ≥ 65 mmHg to ensure organs are getting perfused.
• If MAP < 65, that’s often when we consider vasopressors after fluids are given.

But MAP alone doesn’t tell you the type of shock — it just tells you if perfusion pressure is adequate.

To tell hypovolemic vs. septic shock in your post-op patient, you’d look at other clues alongside MAP:

• Hypovolemic (bleeding): tachycardia, cool clammy skin, low CVP if measured, maybe dropping hemoglobin/hematocrit, surgical drains filling fast.
• Septic (distributive): may also be tachycardic, but skin is often warm/flushed early (due to vasodilation), plus fever, leukocytosis, possible source of infection.

👉 So MAP tells you “do I need a pressor?” but the pattern of other signs tells you which type of shock you’re likely dealing with.

Hypovolemic shock — that picture (low MAP, cool/clammy skin, poor urine output after surgery) fits hypovolemic shock, most likely from ongoing bleeding.

Key reasoning:

• Cool/clammy skin → suggests vasoconstriction (the body is shunting blood to vital organs).
• Low urine output → kidneys aren’t being perfused.
• Surgical context → bleeding is the most common culprit.

In this scenario, the priority isn’t a pressor right away — it’s volume resuscitation (blood, crystalloids) and control of bleeding.

• Pressors like norepinephrine could be used temporarily if MAP stays very low while you’re getting blood ready, but they don’t fix the root problem.

That’s septic (distributive) shock.

Let’s connect it back to vasopressors:

• Septic shock is driven by massive vasodilation → blood vessels are “too wide,” so pressure drops.
• First-line pressor = norepinephrine (because it’s a strong α-adrenergic agonist → vasoconstriction, with some β activity for cardiac support).
• If norepinephrine alone isn’t enough → add vasopressin (works on a different receptor, V1, to clamp down vessels) or sometimes epinephrine.

So, the two “big” types of shock you’ll see in surgical patients actually tie back to two very different pressor strategies:

• Hypovolemic (bleeding): fluids/blood first, norepinephrine only if needed.
• Septic/distributive: norepinephrine right after fluids.

A lot of students assume dopamine is still a go-to pressor, but guidelines have really moved away from it.

Here’s the key reasoning:

• Unreliable effects → dopamine acts on different receptors depending on the dose (dopamine, β1, α1), so its hemodynamic response can be unpredictable.
• More side effects → compared to norepinephrine, dopamine has a higher risk of tachyarrhythmias (like atrial fibrillation).
• Worse outcomes → clinical trials (like SOAP II) showed that dopamine use in shock was associated with higher mortality in cardiogenic shock and more arrhythmias overall.

Because of this, norepinephrine replaced dopamine as the first-line pressor in most guidelines (e.g., Surviving Sepsis Campaign).

👉 Dopamine still occasionally shows up in pediatrics or in select cases (like patients with bradycardia and low cardiac output), but that’s rare.

• Norepinephrine = first-line in septic shock because of its strong α-1 activity → vasoconstriction → raises systemic vascular resistance and MAP.
• It also has some β-1 activity, which gives a bit of cardiac support without the high risk of tachyarrhythmias that dopamine brings.

Here’s a quick framework you can tuck away in your notes:

Pressors by main receptor activity

• Norepinephrine: mostly α1 (vasoconstrictor), some β1 (inotrope).
• Epinephrine: strong α1 and β1 (vasoconstriction + strong inotropy/chronotropy).
• Vasopressin: acts on V1 receptors (vasoconstriction, independent of adrenergic receptors).
• Phenylephrine: pure α1 agonist (vasoconstriction only, no heart effect).
• Dopamine: dose-dependent (low = dopamine receptors, medium = β1, high = α1), but messy and pro-arrhythmic.

Vasopressin is the typical “second-line” add-on in septic shock when norepinephrine alone isn’t enough.

Here’s why that combo makes sense:

• Norepinephrine squeezes vessels via adrenergic receptors.
• Vasopressin works on a completely different receptor (V1). In septic shock, endogenous vasopressin levels are often low, so giving it back helps restore tone.
• Using the two together means you can raise MAP more effectively and often spare how much norepinephrine you need.

Clinical pearl: vasopressin is usually given at a fixed dose (0.03 units/min) rather than titrated up and down like norepinephrine.

Epinephrine is often the next choice when septic shock has a low cardiac output component (i.e., a mixed septic + cardiogenic picture).

Why epinephrine here?

• It stimulates β1 receptors strongly → increases contractility and heart rate (so CO rises).
• It also has α1 activity → adds vasoconstriction if needed.
• Downside: can increase lactate (from β stimulation) and cause more tachyarrhythmias, so it’s usually not first-line unless you really need that inotropic kick.

Other option you might see:

• Dobutamine → mostly β1 agonist, used as a pure inotrope if CO is low but blood pressure is “okay-ish” with norepinephrine.

So the “ladder” looks like:

• Norepinephrine = first-line.
• Add vasopressin if norepi isn’t enough.
• If low cardiac output is the problem → consider epinephrine or sometimes dobutamine.

• Norepinephrine → primary vasoconstrictor, titratable.
• Vasopressin → add-on at fixed dose, helps restore vascular tone through a different pathway.

This way, you’re targeting the main physiology (wide, floppy vessels) without overloading the heart with unnecessary β stimulation.

So here’s a mini-summary you can keep in mind:

Pressors in septic shock

1. Start with norepinephrine.
2. Add vasopressin if norepi requirement is high.
3. Add epinephrine or dobutamine if there’s also poor cardiac output.

B. Norepinephrine

• Rationale: This is likely septic/distributive shock from intra-abdominal infection. Norepinephrine is first-line in septic shock due to strong α1 vasoconstriction with modest β1 support. Dopamine is less predictable and has more arrhythmia risk. Phenylephrine causes pure vasoconstriction without inotropy. Dobutamine is for low-output cardiogenic shock.

B. Ephedrine

• Rationale: Spinal anesthesia can cause vasodilation and bradycardia. Ephedrine provides mixed α/β effects, increasing HR and BP, making it preferred. Phenylephrine is pure α agonist, worsens bradycardia. Norepinephrine is not first-line here. Vasopressin is used in refractory vasoplegia.

A. Dobutamine

• Rationale: This is cardiogenic shock. Dobutamine is a β1 agonist, improving contractility and cardiac output. Norepinephrine may be added if hypotension persists despite inotropy. Phenylephrine worsens afterload. Vasopressin is not useful here.

B. Vasopressin
Explanation: Vasopressin is an effective non-catecholamine vasopressor for refractory septic shock, especially in acidotic states where catecholamines are less effective. Dopamine is not preferred. Phenylephrine may reduce cardiac output. Dobutamine is an inotrope, not a vasopressor, but may be considered if low cardiac output is also present.

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC11215119/
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC2646303/
3. https://scholars.duke.edu/publication/1667037
4. https://www.fip.org/files/content/FIP_members_across_the_globe/FIP_in_China/Consensus_on_Blood_Pressure_Management_in_the_Perioperative_Period_by_Medical_and_Pharmaceutical_Experts.pdf
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC2888327/
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC9552622/
7. https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/am-pdf/10.1111/anae.16206
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC10465094/
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC5247437/
10. https://emcrit.org/pulmcrit/iv-epinephrine-anaphylaxis/
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC2887098/
12. https://www.spandidos-publications.com/10.3892/etm.2016.3432
13. https://www.ncbi.nlm.nih.gov/books/NBK482160/
14. https://www.acc.org/Latest-in-Cardiology/Articles/2022/08/02/12/42/What-You-Need-to-Know-Guidance-For-Clinicians-on-Dobutamine-Shortage
15. https://hospitalprocedures.org/management-of-vasopressor-extravasation-injuries/
16. https://pmc.ncbi.nlm.nih.gov/articles/PMC12140563/
17. https://emcrit.org/ibcc/shock/
18. https://pmc.ncbi.nlm.nih.gov/articles/PMC10488618/
19. https://pmc.ncbi.nlm.nih.gov/articles/PMC10889918/
20. https://ceufast.com/course/vasoactive-drips-a-guide-to-starting-and-titrating-critical-care-drips
21. https://pubmed.ncbi.nlm.nih.gov/25669592/
22. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Adult-Infusion-Standards.pdf